Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Parkin Antikörper (AA 229-465)

PARK2 Reaktivität: Human WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN1869682
  • Target Alle Parkin (PARK2) Antikörper anzeigen
    Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
    Bindungsspezifität
    • 17
    • 16
    • 16
    • 9
    • 8
    • 6
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 229-465
    Reaktivität
    • 75
    • 28
    • 27
    • 6
    • 3
    • 2
    • 1
    • 1
    • 1
    Human
    Wirt
    • 99
    • 7
    • 1
    Kaninchen
    Klonalität
    • 101
    • 6
    Polyklonal
    Konjugat
    • 52
    • 6
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    Dieser Parkin Antikörper ist unkonjugiert
    Applikation
    • 95
    • 39
    • 39
    • 37
    • 21
    • 20
    • 16
    • 16
    • 9
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
    Verwendungszweck
    Polyclonal Antibody to Parkinson Disease Protein 2 (PARK2)
    Spezifität
    The antibody is a rabbit polyclonal antibody raised against PARK2. It has been selected for its ability to recognize PARK2 in immunohistochemical staining and western blotting.
    Kreuzreaktivität
    Schwein, Ratte
    Aufreinigung
    Antigen-specific affinity chromatography followed by Protein A affinity chromatography
    Immunogen
    Recombinant Parkinson Disease Protein 2 (PARK2) corresdonding to Ile229~Val465 with N-terminal His Tag
    Isotyp
    IgG
    Top Product
    Discover our top product PARK2 Primärantikörper
  • Applikationshinweise

    Western blotting: 0.5-2 μg/mL Immunohistochemistry: 5-20 μg/mL Immunocytochemistry: 5-20 μg/mL Optimal working dilutions must be determined by end user.

    Kommentare

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    Lot specific
    Buffer
    PBS, pH 7.4, containing 0.02 % Sodium azide, 50 % glycerol.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
    Handhabung
    Avoid repeated freeze-thaw cycles.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
    Haltbarkeit
    24 months
  • Target
    Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))
    Andere Bezeichnung
    Parkinson Disease Protein 2 (PARK2 Produkte)
    Synonyme
    CG10523 antikoerper, Dmel\\CG10523 antikoerper, Dpark antikoerper, SD01679 antikoerper, dpk antikoerper, AR-JP antikoerper, LPRS2 antikoerper, PDJ antikoerper, PRKN antikoerper, Park antikoerper, Prkn antikoerper, si:ch211-123f21.1 antikoerper, zgc:112390 antikoerper, pdr-1 antikoerper, PARK2 antikoerper, parkin antikoerper, parkin RBR E3 ubiquitin protein ligase antikoerper, Parkinson disease (autosomal recessive, juvenile) 2, parkin antikoerper, park antikoerper, PRKN antikoerper, Prkn antikoerper, prkn antikoerper, CpipJ_CPIJ014867 antikoerper, Park2 antikoerper
    Hintergrund
    AR-JP, LPRS2, PDJ, PRKN, Parkin, Autosomal Recessive,Juvenile, E3 ubiquitin-protein ligase parkin
    Pathways
    Autophagie, Ubiquitin Proteasome Pathway
Sie sind hier:
Kundenservice